ABT is trading just above its 200‑day moving average with RSI around 55 and a bullish MACD crossover, indicating continued upside momentum. Earnings estimates show 8% YoY revenue growth, supporting the technical strength.

Despite recent headlines cautioning investors, market sentiment remains upbeat as the stock benefits from steady valuation and strong pipeline momentum. The broader healthcare rotation and positive analyst coverage keep buying pressure intact.

Long‑term risks include intensifying biosimilar competition and regulatory scrutiny, but Abbott's diversified portfolio and aging‑population tailwinds lock in multi‑digit growth through 2030. The risk‑adjusted outlook remains favorable for patient‑centric innovators.

The 5‑day SMA has broken above the 20‑day SMA with a 15% volume surge, while the ADX rose above 25, confirming a strong trend. These data‑driven signals suggest further short‑term upside.